Table 3.

Adverse events occurring in ≥5% of patients in either treatment group.

	Somapacitan		Norditropin
	%	Rate	%	Rate
Nasopharyngitis	19.7	42.0	25.8	72.1
Headache	11.5	35.6	19.4	65.5
Fatigue	9.8	22.6	16.1	32.8
Dizziness	1.6	3.2	9.7	19.7
Arthralgia	8.2	16.2	6.5	13.1
Abdominal pain	6.6	12.9	0.0	0.0
Asthenia	6.6	16.2	3.2	6.6
Sciatica	6.6	12.9	0.0	0.0
Depression	0.0	0.0	6.5	13.1
Gamma-glutamyltransferase increased	0.0	0.0	6.5	13.1
Central hypothyroidism (secondary)	1.6	3.2	6.5	13.1

Rate, event rate/100 patient-years.